+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Optic Neuropathy - Pipeline Review, H1 2020

  • ID: 5007693
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 70 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Antoxis Ltd
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Regenera Pharma Ltd
  • MORE
Optic Neuropathy - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Optic Neuropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan Plc
  • Antoxis Ltd
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Regenera Pharma Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Optic Neuropathy - Overview
  • Optic Neuropathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Optic Neuropathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Optic Neuropathy - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Antoxis Ltd
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc
  • Regenera Pharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Optic Neuropathy - Drug Profiles
  • aflibercept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brimonidine tartrate implant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSIC-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ELN-41 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fab-3H4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LM-22A4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • QPI-1007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RPh-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Dominant Optic Atrophy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Optic Neuropathy - Dormant Projects
  • Optic Neuropathy - Discontinued Products
  • Optic Neuropathy - Product Development Milestones
  • Featured News & Press Releases
  • May 14, 2019: Regenera announces publication of RPh201 Phase 2a study data for the treatment of NAION in the Journal of Neuro-Ophthalmology
  • Oct 22, 2018: Quark Pharmaceuticals to present data on Optic Neuropathy drug candidate QPI-1007 at AAO 2018 Annual Meeting
  • Aug 06, 2018: Regenera Pharma enrols first patient in Phase lll trial of RPh201
  • Nov 13, 2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007
  • Oct 14, 2016: Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’
  • Sep 19, 2016: Quark Pharmaceuticals to provide an overview on siRNA candidate QPI-1007
  • Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant
  • Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India
  • Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications
  • Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION
  • Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy
  • Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies
  • Jun 24, 2010: Quark Pharmaceuticals Announces Presentation of its siRNA Drug Candidate QPI-1007 at Glaucoma & Retinopathies 2010
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Optic Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Optic Neuropathy - Pipeline by Allergan Plc, H1 2020
  • Optic Neuropathy - Pipeline by Antoxis Ltd, H1 2020
  • Optic Neuropathy - Pipeline by Neurizon Pharma GBR, H1 2020
  • Optic Neuropathy - Pipeline by PharmatrophiX Inc, H1 2020
  • Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H1 2020
  • Optic Neuropathy - Pipeline by Recursion Pharmaceuticals Inc, H1 2020
  • Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H1 2020
  • Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Optic Neuropathy - Dormant Projects, H1 2020
  • Optic Neuropathy - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Optic Neuropathy, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan Plc
  • Antoxis Ltd
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Recursion Pharmaceuticals Inc
  • Regenera Pharma Ltd
  • Regeneron Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll